

Strategy Certificates

Linked to Agriculture Strategy Basket
Issued by UBS AG

Cash settled
SVSP Product Type: Tracker Certificates (1300)
Valor: 12570188 ; ISIN: CH0125701885

Increased by 200'000 Units to 500'000 Units as of 10 May 2011

Increased by 50'000 Units to 300'000 Units as of 07 April 2011

Final Terms

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ss of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA.

1. Description of the Product

Information on Underlying

The basket enables the investor to participate at the net total return (capital appreciation and net dividends through reinvestment) of a selected basket of companies and ETC's. The strategy focuses on global Agricultural stocks and ETC's on Agricultural Commodities rebalanced by the Reference-Portfolio Advisor.

Underlying(s)

Agriculture Strategy Basket
(the "Reference-Portfolio")

Description

Agriculture Strategy Basket (the "Reference-Portfolio") is a notional CHF ("CHF") denominated actively managed Reference-Portfolio, created and maintained by AMG AG, Zug (the "Reference-Portfolio Advisor"). The Reference-Portfolio aims to replicate (i) the performance of a basket of global agricultural stocks and ETC's on commodities (the "Equity Position"), (ii) a FX forward position in order to hedge part of the currency risk (the "FX position", together with the Equity Position the "Constituents"), and (iii) from time to time, a cash position (the "Cash Position", which together with the Constituents shall be referred to as the "Reference-Portfolio Components"), less fees and expenses. The Reference-Portfolio Advisor maintains the Reference-Portfolio in accordance with the attached Reference-Portfolio Guidelines (Annex).

Product Details

| | |
|---------------------|---|
| Security Numbers | Valor: 12570188 / ISIN: CH0125701885 / WKN: UB5JSM |
| Issue Size | Up to 500'000 Units (with reopening clause) |
| Issue Price | CHF 100.00 |
| Stop Loss Level | CHF 10.00 |
| Settlement Currency | CHF |
| Currency Treatment | The Reference-Portfolio can invest in and be exposed to Reference-Portfolio Components denominated in currencies other than the Settlement Currency. The currency risk is not hedged. |

Dates

| | |
|---------------------------|---------------|
| Launch Date | 04 March 2011 |
| Pricing Date ("Pricing") | 04 March 2011 |
| Issue Date / Payment Date | 11 March 2011 |
| Last Trading Day | 11 March 2016 |

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: 41-44-239 14 66*
Private Investors: derivatives@ubs.com

Internet: www.ubs.com/keyinvest

| | |
|--|---|
| Expiration Date | 11 March 2016 (subject to Market Disruption Events, Early Redemption and Stop Loss Event provisions), extendable at the option of the Issuer for additional 5 years periods, on a rolling basis, with a notice period of 180 calendar days. In case this day is not a Business Day, the next following Business day will apply. |
| Redemption Date | 5 Business Days following the Expiration Date (currently expected to be 18 March 2016 (subject to Market Disruption Event provisions)). |
| Closing Date (for Swiss tax purposes) | 1 January, for the first time 1 January 2012 |

Redemption

The Investor is entitled to receive from the Issuer on the Redemption Date an amount per Product in the Settlement Currency of 100% of the Expiration Value.

| | |
|------------------|--|
| Expiration Value | Sum of all Reference-Portfolio Components taking into consideration their respective weightings whereby the Equity Position is valued at the closing price published by the primary exchange of the respective Stocks and ETC's and converted into CHF at the prevailing exchange rate. The FX Position is valued by the Calculation Agent in its reasonable discretion, who may take into consideration factors such as interest and exchange rates for the purpose of such valuation. The calculation also takes into account the effect of all fees and costs associated with the Reference Portfolio. The Reference-Portfolio Level is calculated for each Business Day by the Calculation Agent on the next Business Day. |
|------------------|--|

In the event that a notional investor (in the same position as the Issuer) would be unable to unwind its investments in the Reference-Portfolio Constituents by the Expiration Date, the Issuer reserves the right to extend the Expiration Date to such date where a notional investor in the Reference-Portfolio Components is able to fully unwind the Reference-Portfolio in cash.

Please note that the Expiration Value may be less than the initially invested capital.

| | |
|----------------------------|---|
| Early Redemption by Issuer | The Issuer is entitled to early redeem the Product at the Early Redemption Amount and in full subject to the following notice period: Quarterly, i.e. as of each 31 March, 30 June, 30 September and 31 December (the " Early Redemption Date ") subject to at least 45 Business Days prior notice being given to the Investors. The first possible Early Redemption Date will be 30 June 2011. |
|----------------------------|---|

There is no Early Redemption right for the Investor.

| | |
|-------------------------|---|
| Early Redemption Amount | Sum of all Reference-Portfolio Components taking into consideration their respective weightings whereby the Equity Position is valued at the closing price published by the primary exchange of the respective Stocks and ETC's and converted into CHF at the prevailing exchange rate. The FX Position is valued by the Calculation Agent in its reasonable discretion, who may take into consideration factors such as interest and exchange rates for the purpose of such valuation. The calculation also takes into account the effect of all fees and costs associated with the Reference Portfolio. The Reference-Portfolio Level is calculated for each Business Day by the Calculation Agent on the next Business Day. In the event that a notional investor (in the same position as the Issuer) would be unable to unwind its investments in the Reference-Portfolio Constituents by the Early Redemption Date, the Issuer reserves the right to extend the Early Redemption Date to such date where a notional investor in the Reference-Portfolio Components is able to fully unwind the Reference-Portfolio Components in cash. |
|-------------------------|---|

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 14 66*

Private Investors: derivatives@ubs.com

Internet: www.ubs.com/kevinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

For the avoidance of doubt, the Early Redemption Amount may include (inter alia) any costs arising from the Issuer unwinding any hedges in connection with the Product.

Please note that the Early Redemption Amount may be less than the initially invested capital.

| | |
|-----------------------------|--|
| Reference-Portfolio Level | Sum of all Reference-Portfolio Components taking into consideration their respective weightings whereby the Equity Position is valued at the closing price published by the primary exchange of the respective Stocks and ETC's and converted into CHF at the prevailing exchange rate. The FX Position is valued by the Calculation Agent in its reasonable discretion, who may take into consideration factors such as interest and exchange rates for the purpose of such valuation. The calculation also takes into account the effect of all fees and costs associated with the Reference Portfolio. The Reference-Portfolio Level is calculated for each Business Day by the Calculation Agent on the next Business Day. |
| Dividends | <p>If a Business Day is not an Exchange Business Day for any Constituent, then the price for such Reference-Portfolio Constituent used to calculate the Reference-Portfolio Level will be the price of the previous Exchange Business Day for such Constituent.</p> <p>Any amounts reflecting net dividends of the Reference-Portfolio Constituents will be re-invested into the Reference-Portfolio.</p> |
| Stop Loss Event | A Stop Loss Event shall be deemed to occur if at any time the Product during the period from and including the Fixing Date to and including the Expiration Date trades at or below the Stop Loss Level, as determined by the Calculation Agent. In case of a Stop Loss Event, the Products will automatically be redeemed at the Automatic Redemption Amount. |
| Automatic Redemption Amount | <p>An amount in CHF based on the weighted average of the Reference Portfolio Level over the last five Business Days prior to and including the date on which the Stop Loss Event occurred, as calculated by the Calculation Agent.</p> <p>For the avoidance of doubt, the Automatic Redemption Amount may include (inter alia) any costs arising from the Issuer unwinding any hedges in connection with the Product.</p> |

Please note that the Automatic Redemption Amount may be less than the initially invested capital.

Product Structure

The Product allows for participation in the performance of the Reference-Portfolio. The Reference-Portfolio is a notional actively managed portfolio based on a basket of agricultural stocks and ETC's, Cash and FX Component, maintained by the Reference-Portfolio Advisor according to the attached Reference-Portfolio Guidelines. The Reference-Portfolio aims to replicate the performance level of a basket of agricultural stocks, ETC's on Commodities, from time to time a cash position and a FX component, less fees and expenses.

Since the Reference-Portfolio Level might have a negative value, the Product has a Stop Loss Level, and will be automatically redeemed when a Stop Loss Event has occurred.

General Information

| | |
|-----------------------------|--------------------------------------|
| Issuer | UBS AG, Zurich |
| Issuer Rating | Aa3 Moody's / A+ S&P's / A+ Fitch |
| Lead Manager | UBS AG, Zurich (UBS Investment Bank) |
| Calculation Agent | UBS AG, London Branch |
| Paying Agent | UBS AG, Zurich |
| Reference-Portfolio Advisor | AMG AG, Zug |

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 14 66*

Private Investors: derivatives@ubs.com

Internet: www.ubs.com/kevinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

| | |
|---|--|
| Business Days | Any days in which banks in London, Frankfurt a.M., Zurich, Hong Kong and New York are open for business. |
| Liquidity | UBS intends to offer daily bid/offer prices depending on size, market conditions such as liquidity in the markets of the Reference-Portfolio Components. |
| Reference-Portfolio fees (calculated daily) | Quarterly fee of 0.50% (2.00% per year) of the Reference-Portfolio Level accrued on a daily basis, plus (i) certain expenses commonly to be associated with establishing, maintaining and rebalancing a portfolio similar to the notional portfolio mirrored by the Reference-Portfolio and (ii) the Adjustment Fee, charged by the Calculation Agent and deducted from the Reference-Portfolio Level. The dates of the 0.50% fee deduction are 31 March, 30 June, 30 September and 31 December (in case any of the dates is not a Business Day, the next following Business Day will apply). A part of the Reference-Portfolio Fee will be used to compensate the Reference Portfolio Advisor. |
| Rebalancing | <p>Rebalancing means any change in the Reference-Portfolio Components by the Reference-Portfolio Advisor after the Issue Date. The Calculation Agent has the right to reject Rebalancings under specific circumstances. The expected number of Rebalancings per year is 52.</p> <p>In case of a Rebalancing, secondary market trading of the Product will be suspended until completion of the Rebalancing.</p> |
| Rebalancing / Adjustment Fee | An Adjustment Fee is levied for each adjustment made in the Reference-Portfolio, and represents a percentage of the notional volume of each of the purchase and/or sale of a Constituent. The Adjustment Fee equals 0.10% as at the Launch Date. The Adjustment Fee can be adjusted by the Reference-Portfolio Calculation Agent, but may not amount to more than 0.25%. |
| Minimum Investment | 1 Unit(s) |
| Minimum Trading Lot | 1 Unit(s) |
| Clearing | SIX SIS, Euroclear, Clearstream (registered as intermediated securities with SIX SIS AG, in Switzerland) |
| Form of deed | Uncertificated Securitates |
| Governing Law / Jurisdiction | Switzerland / Zurich |

Tax Treatment Switzerland

| | |
|--------------------------|---|
| Swiss Federal Stamp Duty | The product is not subject to Swiss Stamp Duty. |
| Swiss Federal Income Tax | The taxable income and capital gains/losses will be kept apart and will be reported to the Swiss Federal Tax Administration annually. Taxable income is subject to Swiss Federal, cantonal and communal income tax. |
| Swiss Withholding Tax | The product is not subject to the Swiss withholding tax. |
| EU Savings Tax Treatment | For Swiss paying agents, the product is not subject to the EU Savings tax. |

The tax information only provides a general overview of the potential tax consequences linked to this product at the time of issue. Tax laws and tax doctrine may change, possibly with retroactive effect.

Product Documentation

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 14 66*

Private Investors: derivatives@ubs.com

Internet: www.ubs.com/kevinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

The Final Terms together with the 'General Terms and Conditions for Structured Products on Equity, Commodity and Index Underlyings', as amended from time to time ("**General Terms and Conditions**") shall form the entire documentation for this Product ("**Product Documentation**"), and accordingly the Final Terms should always be read together with the General Terms and Conditions. Definitions used in the Final Terms, but not defined therein shall have the meaning given to them in the General Terms and Conditions. Furthermore, the Final Terms shall serve as and fulfil the requirements of a 'Simplified Prospectus' in accordance with Art. 5 of the Swiss Federal Act on Collective Investment Schemes (CISA). In the event that the Product is listed (see above item 'Listing' under 'General Information'), the Product Documentation will be amended in accordance with the listing requirements of the relevant Exchange.

During the whole term of this Product, the Product Documentation can be ordered free of charge from the Lead Manager at P.O. Box, CH-8098 Zurich (Switzerland), via telephone (+41-(0)44-239 47 03), fax (+41-(0)44-239 69 14) or via e-mail (swiss-prospectus@ubs.com). In addition, the Product Documentation is available on the internet at www.ubs.com/keyinvest.

Notices in connection with this Product shall be validly given by publication in electronic media such as Reuters and/or Investdata. In addition, any changes with regard to the terms of this Product shall be published on the internet at www.ubs.com/keyinvest.

Prudential Supervision

UBS AG is authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). In addition, its London Branch is authorised and regulated by the Financial Services Authority (FSA) and its Jersey Branch by the Jersey Financial Services Commission (JFSC).

2. Prospects of Profits and Losses

| | |
|--------------------|--|
| Market Expectation | Investor expects the positive performance in a basket of agricultural stocks and ETC's on commodities over the life of the Product. In any case the Investors expect that no Stop Loss Event will occur. |
| Risk Tolerance | Investors should be experienced investors and familiar with both derivative products and the stock / commodity markets. The investors must be willing to make an investment that is fully exposed to the performance of the underlying, meaning that Investors might loose their whole investment in the Product in the worst case. The Reference-Portfolio may contain Reference-Portfolio Components denominated in currencies other than the Settlement Currency. The currency risk is not hedged. |
| Profit Potential | The Product allows for participation in positive performance of the Underlying, as adjusted by various fees and expenses as described in more detail above. Furthermore, if prior to the Expiration Date the Investor decides to buy/sell the Product under the Secondary Market terms (as detailed above), the Investor may also be exposed to any funding costs of the Issuer (including, but not limited to, any internal funding costs whether caused by changes in UBS's credit status or otherwise) in relation to the Product. |
| Loss Potential | The Investors may lose some or all of the investment as they are exposed to the negative performance of the Underlying. The Issuer is entitled to redeem the Product early. |

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 14 66*

Private Investors: derivatives@ubs.com

Internet: www.ubs.com/kevinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

3. Significant Risks for Investors

For product specific risks please see above (2. Prospects of Profits and Losses)

Risk Factors relating to the Issuer

In addition to the market risk with regard to the development of the Underlying, each Investor bears the general risk that the financial situation of the Issuer could deteriorate. The Products constitute immediate, unsecured and unsubordinated obligations of the Issuer, which, particularly in case of insolvency of the Issuer, rank pari passu with each and all other current and future unsecured and unsubordinated obligations of the Issuer, with the exception of those that have priority due to mandatory statutory provisions. The general assessment of the Issuer's creditworthiness may affect the value of the Products. This assessment generally depends on the ratings assigned to the Issuer or its affiliated companies by rating agencies such as Moody's, Fitch and Standard & Poor's.

The Issuer Ratings indicated in this document reflect the situation at the time of issuance and may be subject to changes. The actual Issuer Ratings at any given time can be seen on the Issuer's website (www.ubs.com) under "Analysts & Investors".

Secondary Market

The Issuer or the Lead Manager, as applicable, intends, under normal market conditions, to provide bid and offer prices for this Product on a regular basis. However, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide liquidity by means of bid and offer prices for this Product, and assumes no legal obligation to quote any such prices or with respect to the level or determination of such prices. Potential Investors therefore should not rely on the ability to sell this Product at a specific time or at a specific price.

In special market situations, where the Issuer is completely unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices may be temporarily expanded, in order to limit the economic risks of the Issuer.

Market Risk

The investor is exposed to market disruption events (such as trading disruption, exchange disruption and early closure of the relevant exchange), adjustments and early termination which could have an impact on the redemption amount through delay in payment or change in value. For a detailed description of such events and their effects please read the Final Terms and the base prospectus (Base Prospectus Equity).

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 14 66*

Private Investors: derivatives@ubs.com

Internet: www.ubs.com/keinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Important Information

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which this document relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this document. UBS' trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells this Product to dealers and other financial institutions at a discount to the issue price or rebates to them for their account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Products/Notes (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS' prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the Products described herein, save where explicitly stated in the Product Documentation. The Products must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

There is a possibility that costs, including taxes, related to transactions in connection with this Product may arise for the Investor that are not paid by UBS or imposed by it.

Selling Restrictions

Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.

The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.

Europe - Any offer, sale and purchase of this Product must be in compliance with the law of the relevant EEA jurisdiction. Any public offer of this Product within a EEA jurisdiction that has implemented the EU Prospectus Directive (EUPD) shall only be possible if compliant with the requirements of the EUPD.

If the prospectus is either not notified to or the Final Terms are not filed with the relevant Financial Supervisory Authority it DOES NOT QUALIFY as a prospectus published in accordance with the requirements of the EUPD and until a prospectus has been published in accordance with the requirements of the EUPD, this Product may not be offered or sold in EEA jurisdictions that have implemented the EUPD other than 1) in minimum denominations of, or total consideration per investor of at least, EUR 50,000 (or equivalent in other currencies) or 2) only to Qualified Investors; and/or (aggregated for all distributors) to less than 100 offerees that are not Qualified Investors per EEA jurisdiction. A "Qualified Investor" is a legal entity that (i) is authorised or regulated to operate in the financial markets or has the sole purpose to invest in securities; or (ii) meets two of the following three criteria (as shown in its last annual or consolidated accounts): (a) an average number of at least 250 employees during the last financial year; (b) a total balance sheet of more than EUR 43,000,000; and (c) an annual net turnover of more than EUR 50,000,000.

Hong Kong - The contents of this document have not been reviewed by any regulatory authority in Hong Kong. Investors are advised to exercise caution in relation to any offer. If an investor is in any doubt about any of the contents of this document, the investor should obtain independent professional advice.

| | | | |
|--------------------------|--|-----------|--|
| Contact: | UBS AG, P.O. Box, 8098 Zurich | | |
| Institutional Investors: | +41-44-239 14 66* | | |
| Private Investors: | derivatives@ubs.com | Internet: | www.ubs.com/kevinest |

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it.

This Product has not been offered and sold, and each purchaser represents and agrees that it will not offer and sell the Product in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy and sell shares or debentures, whether as principal or agent, or in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32) of Hong Kong or to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance, or in other circumstances which do not result in the document being a "prospectus" within the meaning of the Companies Ordinance. In relation to the issue of this Product, each purchaser represents and agrees that it has not issued and will not issue any advertisement, invitation or document relating to the Product, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the Product which is or is intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the Securities and Futures Ordinance and any rules made thereunder.

Singapore - The following applies subsequent to the coming into force of the amendments to Part XIII of the SFA (as amended by the Securities and Futures (Amendment) Act 2005).

This Document has not been registered as a prospectus with the Monetary Authority of Singapore under the Securities and Futures Act (Cap. 289) of Singapore ("SFA"). Accordingly, this Document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this Product may not be circulated or distributed, nor may this Product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than (i) to an institutional investor specified in Section 274 of the SFA, (ii) to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

In the event where this Product is subscribed or purchased under Section 275 by a relevant person which is:

- (a) a corporation (which is not an accredited investor) the sole business of which is to hold investment and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
 - (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor;
- then the shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest in that trust shall not be transferable for six months after that corporation or that trust has acquired this Product under Section 275 except:
- (1) to an institutional investor under Section 274 of the SFA or to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA;
 - (2) where no consideration is given for the transfer; or
 - (3) by operation of law.

UK - For the purposes of non-discretionary accounts, this Product should not be sold with a consideration of less than 50,000 EUR or equivalent.

USA - This Product may not be sold or offered within the United States or to U.S. persons, the foregoing shall not, however, prohibit sales to U.S. offices of UBS

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 14 66*

Private Investors: derivatives@ubs.com

Internet: www.ubs.com/kevinest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Annex

Reference-Portfolio Guidelines

Agriculture Strategy Basket

Agriculture Strategy Basket (the "**Reference-Portfolio**") is a notional CHF ("CHF") denominated actively managed Reference-Portfolio, created and maintained by AMG AG, Zug (the "**Reference-Portfolio Advisor**"). The Reference-Portfolio aims to replicate (i) the performance of a basket of global agricultural stocks and ETC's on commodities (the "**Equity Position**"), (ii) a FX forward position in order to hedge part of the currency risk (the "**FX position**", together with the Equity Position the "**Constituents**"), and (iii) from time to time, a cash position (the "**Cash Position**", which together with the Constituents shall be referred to as the "**Reference-Portfolio Components**"), less fees and expenses

The Reference-Portfolio Components are selected by the Reference-Portfolio Advisor in accordance with the following guidelines (the "Reference-Portfolio Guidelines"):

1. Only shares (the "Investment Universe") with sufficient liquidity and with exposure to the Agri Sector may be incorporated as Reference-Portfolio Constituents in the Reference-Portfolio ("Eligible Stocks")
2. Besides UBS Exchange Traded Commodities (ETC's) (www.ubs.com/cmci) on Agricultural Commodities, "eligible ETC's" are the following underlyings:

| Name | Primary Exchange | BBG Ticker | Issuer |
|-----------------|------------------|-----------------|-----------------|
| ETC on Wheat | LDN | Wheat LN Equity | ETFS Securities |
| ETC on Corn | LDN | CORN LN Equity | ETFS Securities |
| ETC on Soybeans | LDN | SOYB NL Equity | ETFS Securities |
| ETC on Sugar | LDN | SUGA LN Equity | ETFS Securities |
| ETC on Cotton | LDN | COTN LN Equity | ETFS Securities |
| ETC on Softs | LDN | AIGS LN Equity | ETFS Securities |
| ETC on Coffee | LDN | COFF LN Equity | ETFS Securities |
| ETC on Cocoa | LDN | COCO LN Equity | ETFS Securities |

The maximum exposure to the ETC's within the Reference-Portfolio is limited to 50%.

3. FX Position consists of USD/CHF Forwards with 3month or 6 month maturity. Maximum exposure to the FX position is the USD notional outstanding in USD denominated Stocks within Reference Portfolio. The FX Position aims to hedge part of the currency risk.
4. The Cash Position may at no time exceed 50% of the value of the Reference-Portfolio. No interest will be paid on the Cash Position.

In case of a rebalancing the theoretical volume of a buy or sell order for a Constituent is limited to 200% of the average traded daily volume of that Constituent. A rebalancing may happen at the discretion of the Reference-Portfolio Advisor. The Calculation Agent has the right to reject constituents that form part of a Rebalancing. The theoretical volume is defined as the number of outstanding Certificates multiplied by the Reference-Portfolio Level (using a reasonable foreign exchange rate to convert into the currency of the Constituent) and multiplied by the change in the percentage weight of the Constituent. The average traded daily volume is defined as the 30 Day average trading turnover. The expected number of Rebalancings per year is 52.

At any time, the Reference-Portfolio may reflect a cash position which mirrors the holding of cash, money market instruments or cash obligations (the "Cash Position").

A Quarterly fee of 0.50% (2.00% per year) of the Reference-Portfolio Level accrued on a daily basis, plus (i) certain expenses commonly to be associated with establishing, maintaining and rebalancing a portfolio similar to the notional portfolio mirrored by the Reference-Portfolio and (ii) the Adjustment Fee, charged by the Calculation Agent and deducted from the Reference-Portfolio Level. The dates of the 0.50% fee deduction are 31 March, 30 June, 30 September and 31 December (in case any of the dates is not a Business Day, the next following Business Day will apply). A part of the Reference-Portfolio Fee will be used to compensate the Reference Portfolio Advisor.

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 14 66*

Private Investors: derivatives@ubs.com

Internet: www.ubs.com/kevinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

An Adjustment Fee is levied for each adjustment made in the Reference-Portfolio, and represents a percentage of the notional volume of each of the purchase and/or sale of an Eligible Stock or ETC. The Adjustment Fee was set by the Reference-Portfolio Advisor in accordance with the Reference-Portfolio Calculation Agent at 0.10% as at the Launch Date. The Adjustment Fee can be adjusted by the Reference-Portfolio Calculation Agent, but may not amount to more than 0.25%. The Reference-Portfolio Fee is accrued on a daily basis and paid on a quarterly basis, on 31 March, 30 June, 30 September and 31 December should any of these dates fall on a day which is not a Business Day, the Fee is paid on the next Business Day).

The Reference-Portfolio is denominated in CHF, while the Constituents, notionally comprised in the Reference-Portfolio, might be denominated in other currencies than CHF. In order to appropriately reflect the performance of the Constituents in the determination of the value of the Reference-Portfolio, the value of the Constituents denominated in other currencies than CHF is expressed in CHF. The exchange rate equals the currently prevailing exchange rate. The exchange-rate risk is not mitigated.

The above Universe can be amended in agreement between the Calculation Agent and the Reference-Portfolio Advisor. The Calculation Agent has the right to reject Constituents that form part of a Rebalancing.

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 14 66*

Private Investors: derivatives@ubs.com

Internet: www.ubs.com/keinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.